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ABSTRACT 
RECQL1, a key member of the RecQ family of DNA helicases, is required for DNA 
replication and DNA repair. Two recent studies have shown that germ-line RECQL1 
mutations are associated with increased breast cancer susceptibility. Whether altered 
RECQL1 expression has clinicopathological significance in sporadic breast cancers is 
unknown. We evaluated RECQL1 at the transcriptomic level [METABRIC cohort, n=1977] 
and at the protein level [cohort 1, n=897; cohort 2, n= 252; cohort 3 (BRCA-germline 
deficient), n=74].  In RECQL1-depleted breast cancer cells we investigated anthracycline 
sensitivity. High RECQL1 mRNA was associated with intClust.3 (p=0.026) which is 
characterised by low genomic instability. On the other hand, low RECQL1 mRNA was 
linked to intClust.8 (luminal A ER+ sub-group) (p=0.0455) and intClust.9 (luminal B ER+ 
sub-group) (p=0.0346) molecular phenotypes. Low RECQL1 expression was associated with 
shorter breast cancer specific survival (p=0.001). At the protein level, low nuclear RECQL1 
level was associated with larger tumour size, lymph node positivity, high tumour grade , high 
mitotic index, pleomorphism, de-differentiation, ER negativity and HER-2 overexpression (p 
values<0.05). In ER+ tumours that received endocrine therapy, low RECQL1 was associated 
with poor survival (p=0.008). However, in ER- negative tumours that received anthracycline 
based chemotherapy, high RECQL1 was associated with poor survival (p=0.048). In 
RECQL1-depleted breast cancer cell lines we confirmed doxorubicin sensitivity which was 
associated with DNA double strand breaks accumulation, S-phase cell cycle arrest and 
apoptosis. We conclude that RECQL1 has prognostic and predictive significance in breast 
cancers. 
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INTRODUCTION 
DNA helicases unwind DNA, a process essential during replication and DNA repair. Human 
RecQ family of DNA helicases includes RECQL1, RECQL4, RECQL5, BLM and WRN (1, 
2). RECQL1 (also known as RECQL or RECQ1) is localised to chromosome 12p12 and 
encodes a 649 amino acid protein (3-6). RECQL1 is the smallest and the most abundant of 
human RecQ helicases. RECQL1 is an integral component of the replication complex and is 
required for the maintenance of replication fork progression (7-9). RECQL1 is also essential 
for the maintenance of genomic stability through roles in DNA repair. RECQL1, besides a 
DNA 3’-5’ helicase activity, can promote branch migration of Holliday junctions and also has 
strand annealing activity (10). Moreover, to accomplish its various biological functions 
RECQL1 is known to interact with various proteins involved in DNA repair including 
PARP1, RPA, RAD51, Top3α, EXO1, MSH2/6, MLH1-PMS2 and Ku70/80 (3-6). The 
essential role played by RECQL1 in DNA repair is underpinned by the fact that RECQL1 
depletion in cells results in increased frequency of spontaneous sister chromatid exchanges, 
chromosomal instability, DNA damage accumulation and increased sensitivity to cytotoxic 
chemotherapy (11). 
Emerging data suggest a role for RECQL1 in breast cancer pathogenesis. Importantly, two 
recent studies have shown that germ-line RECQL1 mutations are associated with increased 
breast cancer susceptibility (12-14). Sun et.al. have identified pathogeneic mutations in 
RECQL1 gene in 9/448 Chinese patients with BRCA- negative familial breast cancers (12). 
Similarly, Cybulski et.al. identified deleterious mutations in 7/1013 and 30/13,136 Polish 
breast cancer patients (13). Although germ-line mutations in RECQL1 are rare, the data 
provides evidence that RECQL1 is a tumour suppressor. However whether RECQL1 also 
influences sporadic breast cancer pathogenesis and prognosis is currently unknown.   
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In the current study we have comprehensively investigated RECQL1 in large cohorts of 
sporadic breast cancer and have provided the first clinical evidence that altered RECQL1 
expression is associated with aggressive breast cancers and poor prognosis.  Pre-clinically, 
RECQL1 depletion in breast cancer cells increased anthracycline chemosensitivity. We 
conclude that RECQL1 expression has prognostic and predictive significance in sporadic 
breast cancers.  
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METHODS 
Clinical study 
RECQL1 mRNA expression in breast cancer: RECQL1 mRNA expression was 
investigated in METABRIC (Molecular Taxonomy of Breast Cancer International 
Consortium) cohort. The METABRIC study protocol, detailing the molecular profiling 
methodology in a cohort of 1977 breast cancer samples is described by Curtis et al (15).  
Patient demographics are summarised in supplementary Table S1 of supporting 
information. ER positive and/or lymph node negative patients did not receive adjuvant 
chemotherapy.  ER negative and/or lymphnode positive patients received adjuvant 
chemotherapy. For   this   cohort, the mRNA expression   was   hybridized   to   Illumina   
HT-12 v3 platform (Bead Arrays), and the data were pre-processed and normalised as 
described previously. RECQL1 expression was evaluated in this data set (RECQL1 probe ID: 
ILMN_1692705).  The probe was a perfect match and quality for its target, having a GC 
content of 58%, 0 SNPs and it does not possess a polyG tail at the end.  Samples were 
classified into the intrinsic subtypes based on the PAM50   gene   list. A   description   of   the   
normalisation, segmentation, and statistical analyses was previously described (15).   Real 
time RT-qPCR was performed on the ABI Prism 7900HT sequence detection system   
(Applied   Biosystems)   using   SYBR1 Green   reporter.   All   the samples were analysed as 
triplicates. The Chi-square test was used for testing association between categorical variables, 
and a multivariate Cox model was fitted to the data using as endpoint breast cancer specific 
death.  Xtile (Version 3.6.1) was used to identify a cut-off in gene expression values such that 
the resulting subgroups had significantly different survival courses (16).  
RECQL1 protein expression in breast cancer: The study was performed in a consecutive 
series of 1650 patients with primary invasive breast carcinomas who were diagnosed between 
1986 and 1999 and entered into the Nottingham Tenovus Primary Breast Carcinoma series.  
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Patient demographics are summarised in Supplementary Table S2. This is a well-
characterised series of patients with long-term follow-up that have been investigated in a 
wide range of biomarker studies (17-23).  All patients were treated in a uniform way in a 
single institution with standard surgery (mastectomy or wide local excision), followed by 
Radiotherapy.   Prior to 1989, patients did not receive systemic adjuvant treatment (AT). 
After 1989, AT was scheduled based on prognostic and predictive factor status, including 
Nottingham Prognostic Index (NPI), oestrogen receptor-α (ER-α) status, and menopausal 
status. Patients with NPI scores of <3.4 (low risk) did not receive AT. In pre-menopausal 
patients with NPI scores of ≥3.4 (high risk), classical Cyclophosphamide, Methotrexate, and 
5-Flurouracil (CMF) chemotherapy was given; patients with ER-α positive tumours were also 
offered endocrine therapy. Postmenopausal patients with NPI scores of ≥3.4 and ER-α 
positivity were offered endocrine therapy, while ER-α negative patients received classical 
CMF chemotherapy. Median follow up was 111 months (range 1 to 233 months).  Survival 
data, including breast cancer specific survival (BCSS), disease-free survival (DFS), and 
development of loco-regional and distant metastases (DM), was maintained on a prospective 
basis.  DFS was defined as the number of months from diagnosis to the occurrence of local 
recurrence, local lymph node (LN) relapse or DM relapse.  Breast cancer specific survival 
(BCSS) was defined as the number of months from diagnosis to the occurrence of BC 
related-death. Local recurrence free survival (LRS) was defined as the number of months 
from diagnosis to the occurrence of local recurrence. DM-free survival was defined as the 
number of months from diagnosis to the occurrence of DM relapse.  Survival was censored if 
the patient was still alive at the time of analysis, lost to follow-up, or died from other causes. 
We also evaluated an independent series of 252 ER-α negative invasive BCs diagnosed and 
managed at the Nottingham University Hospitals between 1999 and 2007.  All patients were 
primarily treated with surgery, followed by radiotherapy and anthracycline chemotherapy. 
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The characteristics of this cohort are summarised in supplementary Table S3. In addition we 
also explored RECQL1 expression in a cohort of BRCA germ-line deficient tumours. Patient 
demographics in this cohort is summarised in supplementary Table S4. 
Tumor Marker Prognostic Studies (REMARK) criteria, recommended by McShane et al (24), 
were followed throughout this study.  Ethical approval was obtained from the Nottingham 
Research Ethics Committee (C202313).  
Tissue Microarrays (TMAs) and immunohistochemistry (IHC): Tumours were arrayed in 
tissue microarrays (TMAs) constructed with 0.6mm cores sampled from the periphery of the 
tumours. The TMAs were immunohistochemically profiled for RECQL1 and other biological 
antibodies (Supplementary Table S5) as previously described (18, 19, 21, 23).  
Immunohistochemical staining was performed using the Thermo Scientific Shandon 
Sequenza chamber system (REF: 72110017), in combination with the Novolink Max Polymer 
Detection System (RE7280-K: 1250 tests), and the Leica Bond Primary Antibody Diluent 
(AR9352), each used according to the manufacturer’s instructions (Leica Microsystems).  
Leica Autostainer XL machine was used to dewax and rehydrate the slides. Pre-treatment 
antigen retrieval was performed on the TMA sections using sodium citrate buffer (pH 6.0) 
and heated for 20 minutes at 950C in a microwave (Whirpool JT359 Jet Chef 1000W). A set 
of slides were incubated for 60 minutes with the primary anti-RECQL1 antibody (Bethyl 
Laboratories, catalog no. A300-450A) at a dilution of 1:1000 respectively. Negative and 
positive (by omission of the primary antibody and IgG-matched serum) controls were 
included in each run. The negative control ensured that all the staining was produced from the 
specific interaction between antibody and antigen. 
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Evaluation of immune staining: Whole field inspection of the core was scored and 
intensities of nuclear staining were grouped as follows: 0 = no staining, 1 = weak staining, 2 
= moderate staining, 3 = strong staining. The percentage of each category was estimated (0-
100%).  H-score (range 0-300) was calculated by multiplying intensity of staining and 
percentage staining. RECQL1 expression was categorised based on the frequency histogram 
distributions. The tumour cores were evaluated by two scorers (AA and MA) and the 
concordance between the two scorers was excellent (k = 0.79). Xtile (Version 3.6.1) was used 
to identify a cut-off in protein expression values such that the resulting subgroups had 
significantly different survival courses.  An H score of ≥215 was taken as the cut-off for high 
RECQL1 level. Not all cores within the TMA were suitable for IHC assessments as some 
cores were missing or containing inadequate invasive cancer (<15% tumour).  
Statistical analysis: Data analysis was performed using SPSS (SPSS, version 17 Chicago, 
IL). Where appropriate, Pearson’s Chi-square, Fisher’s exact, Student’s t and ANOVA one 
way tests were used. Cumulative survival probabilities were estimated using the Kaplan–
Meier method, and differences between survival rates were tested for significance using the 
log-rank test. Multivariate analysis for survival was performed using the Cox proportional 
hazard model. The proportional hazards assumption was tested using standard log-log plots. 
Hazard ratios (HR) and 95% confidence intervals (95% CI) were estimated for each variable. 
All tests were two-sided with a 95% CI and a p value <0.05 considered significant. For 
multiple comparisons, p values were adjusted according to Benjamini-Hochberg method (25). 
Breast cancer cell lines and culture: MCF-7 (ER+/PR+/HER2-, BRCA1 proficient), MDA-
MB-231 (ER-/PR-/HER2-, BRCA1 proficient), MDA-MB-468 (ER-/PR-/HER2-, BRCA1 
proficient) and MDA-MB-436 (ER-/PR-/HER2-, BRCA1 deficient) were purchased from 
ATCC and were grown in RPMI (MCF-7) or DMEM (MDA-MB-231, MDA-MB-468 and 
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MDA-MB-436) medium with the addition of 10% foetal bovine serum and 1% 
penicillin/streptomycin. Cells in culture were routinely checked for mycoplasma 
contamination by PCR (Sigma, catalog no.  MP0035).The cells characterisation were 
performed by ATCC and passaged in the laboratory for fewer than 6 months. 
 
RECQL1 depletion in breast cancer cells: On-Target plus SMARTpool small interfering 
RNAs (siRNAs) against RECQL1 (NM_032941), and non-targeting control (CTL) were 
purchased from Dharmacon (catalog nos.  L-013597-00-0005 and D-001810-10-05, 
respectively).  We have previously established the specificity of the siRNA pool (5).  All 
siRNA transfections (in MCF-7, MDA-MB-231 and MDA-MB-468 breast cancer cells) were 
performed by reverse transfection at a final concentration of 20 nM using Lipofectamine 
RNAiMAX (Invitrogen, catalog no. 13-778-075) as instructed by the manufacturer.  Stable 
shRNA-mediated knockdown of RECQL1 in MDA-MB-231 cells was achieved using a 
lentiviral system (26).  Briefly, lentivirus particles were produced by cotransfecting 293T 
cells with the pLKO.1 lentiviral shRNA expression vector containing the RECQL1 targeting 
sequence (5”-GAGCTTATGTTACCAGTTA-3”) or the gene encoding Luciferase (5”-
ACGCTGAGTACTTCGAAATGT-3”) with the packaging plasmids psPAX2 and pM2D.G; 
and used to transduce MDA-MB-231 cells, followed by selection with puromycin (8 µg/ml).  
All cells were cultured in a humidified atmosphere containing 5% CO2 at 37oC and routinely 
checked for mycoplasma contamination (Sigma, catalog no.  MP0035).  The level of 
RECQL1 depletion was verified by western blotting. 
 
Western Blot Analysis: Whole-cell lysates were prepared in radioimmunoprecipitation assay 
(RIPA) buffer containing protease inhibitor cocktail (Sigma, catalog no. 11873580001), and 
protein was quantified using Bio-Rad DC protein assay kit (Bio-Rad, catalog no. 5000111).  
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Fifty microgram of total protein per lane was used for immunoblotting.  The following 
primary antibodies were used:  RECQL1 (1:1000; Bethyl Laboratories, catalog no. A300-
450A), γH2AX (1:1000; Cell Signaling, catalog no. 2577), GAPDH (1:1000; Cell Signaling, 
catalog no. 5174), ERα (1:100, EP1 clone, Dako, catalog no. IS08430-2.), and β actin 
(1:10000; Abcam, catalog no. ab8226). Following incubation with infrared dye-labelled (Li-
Cor) [IRDye 800CW Mouse Anti-Rabbit IgG and IRDye 680CW Rabbit Anti-Mouse IgG; 
1:10000] or HRP-conjugated secondary antibodies (Vector Laboratories) for 1 h, membranes 
were scanned with a Li-Cor Odyssey machine (700 and 800nm) or GeneGnome XRQ 
Chemidoc System (Syngene) to determine protein expression and signal intensities were 
quantified using ImageJ. 
 
Quantitative real time PCR: Total RNA was extracted from MCF-7, MDA-MB-231, 
MDA-MB-468 and MDA-MB-436 cells using RNeasy Mini kit (QIAGEN, UK). The 
quantification of the extracted RNA was done using a NanoDrop 2000c Spectrophotometer 
(Thermo Scientific). The cDNA was synthesised from 0.5 μg of total RNA using RT2 first 
strand kit (QIAGEN). The real-time qPCR was performed using SYBR Green PCR Master 
mix (Applied Biosystems) with primer set (RECQL1 QuantiTect Primer Assay, catalog no. 
QT00034503, QIAGEN) targeting RECQL1 gene. The glyceraldehyde-3-phosphate 
dehydrogenase housekeeper gene was used as an internal control (GAPDH QuantiTect Prier 
Assay, catalog no. QT00079247, QIAGEN). The real-time PCR for each RNA sample was 
performed in triplicate. NTC (No Template Control) was used to rule out cross contamination 
of reagents and surfaces. NTC included all the RT-PCR reagents except the RNA template. 
Minus reverse transcriptase (- RT) control was used to rule out genomic DNA contamination. 
 
12 
 
Cytotoxicity and cell cycle analysis: Cells, stably transduced or 48 h after siRNA 
transfection, plated in quadruplicates into a 96-well plate (5x103 cells/well) were treated with 
increasing concentrations of doxorubicin and cell viability was measured after 5 days by the 
WST-8 based colorimetric assay using Cell Counting Kit-8 (Dojindo Laboratories) according 
to the manufacturer’s instructions.  For cell cycle analysis, cells were fixed in cold ethanol 
before being stained with propidium iodide (Sigma, 0.45 mg/mL).  Resuspended cells were 
analysed for DNA content by flow cytometry performed on a BD Accuri C6 flow cytometer 
equipped with BD Accuri C6 software (BD Biosciences). Means from two independent 
experiments were plotted with their respective standard errors of the means (SEM).  
Statistically significant differences between cell populations was confirmed using a 2-tailed t-
test, assuming equal variances and are presented on figures as *= p ≤ 0.05, ** = p ≤ 0.005. 
 
Immunofluorescence staining analysis: For γH2AX staining, control and RECQL1 
knockdown cells were grown on coverslips in the medium containing 0.1 µM doxorubicin for 
4 h and allowed to recover in drug free medium for indicated time periods.  Cells were fixed 
in 3.75% paraformaldehyde for 10 min at room temperature, permeabilized in 0.5% Triton-
X100 in PBS for 10 min and blocked with 1% BSA in PBS for 1 h at room temperature 
followed by incubation with mouse monoclonal anti-γH2AX (1:200; Upstate, JBW301) 
antibody for 1 h at 37°C.  After three washes in PBS for 5 min each, the cells were incubated 
with Alexa Fluor 488 goat anti-mouse IgG (1:400; Invitrogen) secondary antibody for 1 h at 
37°C, washed thrice with PBS and mounted in Prolong Gold containing DAPI (Invitrogen).  
Immunostained cells were imaged with a Nikon fluorescence microscope (Eclipse Ti) 
equipped with imaging capabilities and Elements imaging software.  Scoring for each 
individual condition (siRNA or shRNA, cell line, drug treatment etc.) within an experiment 
was carried out on at least 10 separate fields of view and about 50-100 cells in total.  Means 
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from two independent experiments were plotted with their respective standard errors of the 
means (SEM).  Statistically significant differences between cell populations was confirmed 
using a 2-tailed t-test, assuming equal variances and are presented on figures as *= p ≤ 0.05, 
** = p ≤ 0.005. 
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RESULTS 
 
RECQL1 mRNA expression in human breast cancer: We then evaluated RECQL1 mRNA 
expression in the METABRIC cohort.  31.7% (626/1971) of breast tumours had low 
RECQL1 mRNA expression and 68.3% (1345/1971) of breast tumours had high RECQL1 
mRNA expression. Clinicopathological associations are summarized in Supplementary 
Table S6. The METABRIC study by joint clustering of copy number and gene expression 
data identified 10 novel biological subgroups [labelled integrative clusters (intClust) 1-10] 
(15).   We investigated whether RECQL1 mRNA expression would associate with these 
distinct biological subgroups (Supplementary Table S7). High RECQL1 mRNA was 
associated with intClust.3 (p=0.026) which is characterised by low genomic instability (15). 
On the other hand low RECQL1 mRNA was linked to intClust.8 (p=0.0455) and intClust.9 
(p=0.0346) phenotypes. Of note, intClust.8 belongs to Luminal A ER+ sub-group where as 
intClust.9 belongs to luminal B ER+ sub-group (15). 
 
We then proceeded to survival analysis in the METABRIC cohort. Low RECQL1 mRNA 
expression was associated with poor BCSS (p=0.001) in the whole cohort [Figure 1B]. In  
ER+ tumours, low RECQL1 mRNA expression remained associated with poor BCSS 
(p=0.001) [Figure 1C], including in patients who received adjuvant endocrine therapy 
(p=0.003) [Figure 1D]. However, in ER- tumours, RECQL1 mRNA expression, although 
borderline, did not significantly influence outcome in the ER- cohort, including in patients 
who received adjuvant chemotherapy (p=0.071 and p=0.071 respectively) [Figure 2E, 2F].  
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Together the data provides evidence that RECQL1 mRNA level has clinicopathological and 
prognostic significance in various sub-types of breast cancers. We then proceeded to evaluate 
RECQL1 protein level in breast cancers. 
 
RECQL1 protein level in human breast cancer:  A total of 897 early breast cancers were 
suitable for RECQL1 expression analysis. We observed only nuclear expression where 
677/897 (75.5%) of tumours had low RECQL1 level and 220/897 (25.5%) had high RECQL1 
level (Figure 2B).  We also evaluated 15 normal breast tissues for RECQL1 expression 
where high nuclear staining in the terminal duct lobular units in the sections was observed 
(mean H-score =226) suggesting differential expression of RECQL1 in breast cancer tissues 
compared to normal breast tissue. No cytoplasmic staining was observed in any normal breast 
or tumour tissue. 
 
As shown in Table 1, in the whole cohort, low nuclear RECQL1 levels were significantly 
associated with larger tumour size, lymph node positivity, higher tumour stage,  high tumour 
grade, high mitotic index, pleomorphism, de-differentiation and tumour type (ps<0.05). ER-, 
PR- and HER-2 overexpression was more common in tumours with low nuclear RECQL1 
protein level (p<0.05). High risk Nottingham Prognostic Index (NPI) >3.4 was also more 
common in tumours with low RECQL1 level (p=0.0006). Low PARP1, BRCA1 negative, 
low RAD51, low ATM, low nuclear pChk1, low nuclear Chk2, low XRCC1, low FEN1, low 
SMUG1, low DNA-PKcs were significantly more likely in tumours with low nuclear 
RECQL1 protein level (p<0.05). Moreover, low RECQL1 tumours were also significantly 
associated with low levels of other RecQ helicases including RECQL4, BLM and WRN 
(ps<0.05).  We then proceeded to analysis separately in ER+ and ER- cohort. 
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In ER+ tumour (supplementary Table S7), low nuclear RECQL1 level was significantly 
associated with higher mitotic index (p= 0.033). PR- and High risk Nottingham Prognostic 
Index (NPI) >3.4 was also more common in tumours with low RECQL1 level (p 
values<0.05). Low XRCC1, low TOPO2A, were also more likely in tumours with low 
nuclear RECQL1 protein level (p<0.05). However, in ER- tumours (supplementary Table 
S8), no significant clinicopathological associations were observed. 
We then proceeded to survival analyses. In the whole cohort, patients whose tumours had low 
RECQL1 level were significantly more likely to have shorter BCSS compared to those with 
high RECQL1 level (p=0.001) (Figure 2C). In ER+ tumours, similarly, low RECQL1 was 
associated with poor BCSS (p = 0.008) (Figure 2D) including in patients who received 
adjuvant endocrine therapy (p= 0.021) (Figure 2E). However, in patients who received no 
endocrine therapy, RECQL1 level did not influence survival (p=0.485) (Supplementary 
Figure S1A). In ER- tumours, RECQL1 did not influence survival including in patients who 
received CMF (cyclophosphamide+methotrexate+5-FU) chemotherapy (Supplementary 
Figure S1B, C and D). However, in this historical cohort, patients received CMF 
chemotherapy which is currently not the standard adjuvant treatment in breast cancer. We 
therefore investigated RECQL1 level and survival in a further cohort of 252 ER- tumours that 
received more modern anthracycline based adjuvant chemotherapies. The characteristics of 
this cohort are summarised in supplementary Table S3. As the long term follow-up data has 
not yet matured, we investigated the impact of RECQL1 expression on disease free survival 
at 5 years in patients who received adjuvant doxorubicin chemotherapy. At 5 years, 176/252 
were alive, 73/252 were dead from breast cancer recurrence and 3/252 died from other 
causes.  Patients with high RECQL1 expression were more likely to suffer disease recurrence 
compared to patients with low RECQL1 expression (p=0.048) (Figure 2F).  
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We also investigated RECQL1 expression in 49 BRCA1 germ-line deficient and 25 BRCA2 
germ-line deficient breast tumours. No significant clinicopathological associations were 
observed (data not shown). RECQL1 expression also did not influence survival outcomes 
BRCA1/2 germ-line deficient tumours (data not shown).  
Taken together, the data suggests that RECQL1 overexpression may predict resistance to 
doxorubicin chemotherapy in sporadic ER- breast cancers. To investigate this possibility 
further we proceeded to pre-clinical studies in breast cancer cell lines. 
  
RECQL1 depletion and doxorubicin chemosensitivity in breast cancer cell lines:  
RECQL1 deficiency leads to genomic instability and sensitivity to a range of genotoxins (3-
6). However, the impact of RECQL1 depletion in breast cancer cells and anthracycline 
sensitivity has not been investigated.  
We initially profiled MCF-7, MDA-MB-468 and MDA-MB 231 breast cancer cell lines. At 
the mRNA level, MCF-7 and MDA-MB-231 cells have high RECQL1 mRNA expression 
compared to MDA-MB-468 cells (Figure 3A). At the protein level, all three cell lines have 
robust RECQL1 protein expression (Figure 3B).  We then utilised siRNA to transiently 
deplete RECQL1 in MDA-MB-468, MDA-MB-231 and MCF-7 cells. We transfected cells 
with a control siRNA (siControl) or a pool of 4 siRNAs (smart pool, 20 nM) targeting 
RECQL1 (siRECQL1) (Figures 3C1, 3D1 & supplementary Figure S2A1).  As compared 
to control cells, RECQL1 depleted cells displayed significantly reduced survival to 
doxorubicin treatment in MDA-MB-468, MDA-MB 231 (Figure 3C2, 3D2) and MCF-7 
cells (supplementary Figure S2A2) (p<0.05 at all drug concentration tested). To determine 
if increased sensitivity to doxorubicin was also sustained in cells depleted of RECQL1 over a 
longer period of time, we transduced MDA-MB-231 cells with a RECQL1-specific shRNA 
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(Figure 3E1).  As compared to control shRNA (shCTL) transduced MDA-MB-231 cells, the 
RECQL1 shRNA (shRECQL1) transduced cells displayed significantly reduced survival to 
doxorubicin treatment (Figure 3E2).  
 
To determine whether the cellular level of RECQL1 protein modulates overall DNA damage 
in breast cancer cell lines, we examined γH2AX as a surrogate of DNA double-strand breaks 
in control and RECQL1 knockdown cells exposed to doxorubicin. MDA-MB-231 cells stably 
transduced with control or RECQL1 shRNA were treated with 0.1 µM doxorubicin for 4 h 
and the percentage of cells exhibiting ≥5 γH2AX foci at various time points following 
recovery from drug treatment was determined by immunofluorescence (Figure 3F). 
Consistent with constitutively elevated DNA damage upon RECQL1 knockdown reported in 
other cell types (8, 27), RECQL1-depleted MDA-MB-231 cells displayed spontaneous 
γH2AX foci under untreated condition. Doxorubicin treatment induced comparable level of 
DNA double strand breaks in both control and RECQL1 knockdown MDA-MB-231 cells. 
However, following 8 h recovery from the doxorubicin treatment, significantly greater 
fraction of RECQL1-depleted cells was scored positive for γH2AX foci. After 24 h in drug-
free medium, γH2AX foci were persistent in about 25% RECQL1-depleted cells as compared 
to 5% control MDA-MB-231 cells (Figure 3G). We note that the initial numbers of γH2AX 
positive induced spontaneously in control versus RECQL1-depleted cells is different, 
however, the difference between control and RECQL1 knockdown cells for the percentage of 
γH2AX positive cells during recovery (8 and 24 h) from doxorubicin treatment is statistically 
significant (p≤0.05). These results suggest that RECQL1 promotes repair of doxorubicin 
induced DNA damage.  In MCF-7 cells, similarly, RECQL1-depleted cells retain statistically 
significant proportion of γH2AX positive cells at 8 and 24 h following recovery in drug-free 
medium (Supplementary Figure S2B).  
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We next analysed cell cycle progression in these cells using FACS analysis (Figure 4). 
Stable knockdown of RECQL1 in MDA-MB-231 cells resulted in predominant accumulation 
in G0/G1 phase of the cell cycle. Cell cycle distribution of control and RECQL1 knockdown 
MDA-MB-231 cells was largely unaltered after doxorubicin treatment (0.1 µM, 4 h). MDA-
MB-231 cells, with or without knockdown of RECQL1 expression, accumulated in S-phase 
following 8 h after recovery from treatment, and in G2/M following 24 h recovery in drug-
free medium; however, a significantly greater proportion of RECQL1-depleted cells 
remained in S-phase at 8 h (p≤0.05) and 24 h (p≤0.05) of recovery (Figure 4A & 4B). 
Doxorubicin induced S-phase arrest is consistent with the formation of DNA adducts that 
prevent replication fork progression and formation of double strand breaks downstream of 
Topoisomerase II inhibition. Relative accumulation in the S-phase together with the increased 
double strand breaks and sensitivity to doxorubicin observed in RECQL1 knockdown MDA-
MB-231 cells is consistent with a role of RECQL1 in resolving stalled or broken replication 
forks and DNA repair. Doxorubicin induced DNA strand breaks can ultimately result in 
apoptosis.  To determine the extent of doxorubicin induced cell death in RECQL1 
knockdown cells, we analysed the percentage of MDA-MB-231 cells stably transduced with 
control or RECQL1 shRNA having sub-G1 DNA content (Figure 4C& 4D). Following 
treatment with doxorubicin (0.1 µM) for 24 h, 9±1.73% control and 15±2.61% RECQL1 
knockdown cells were in the sub-G1 population; treatment for 48 h resulted in 13±2.04% 
control and 19.2±2.01% RECQL1 knockdown cells in sub-G1 population(Figure 4C& 4D). 
In RECQL1-depleted MCF-7 cells, although S- phase accumulation was not evident 
Supplementary Figure S2C, there was significant accumulation of sub-G1 cells upon 24 h 
and 48 h of doxorubicin treatment (Supplementary Figure S2D).  
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RECQL1 depletion and estrogen receptor- α (ER α) levels: Given the recent evidence that 
RECQL1 may modulate gene expression (26, 28), we conducted preliminary studies to 
explore if RECQL1 may impact upon ERα expression in breast cancer cell lines. In control 
cells, as expected, ERα expression was not detectable in MDA-MB-468 cells and MCF-7 
cells have proficient ERα expression. We detected ERα expression in MDA-MB-231. 
Although unexpected, previous studies have reported ERα expression in MDA-MB-231 cells 
(29, 30).  As shown in supplementary Figure S3, 48 h after RECQL1 siRNA transfection, 
we observed significant depletion of ERα levels in MCF-7 and MDA-MB-231 cells.  The 
data suggest that either RECQL1 depletion impairs ERα expression or promotes ERα 
degradation. Detailed mechanistic studies are currently underway to explore these 
possibilities. 
 
Taken together, preclinical and clinical data provide evidence that RECQL1 has prognostic 
and predictive significance in breast cancers.   
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DISCUSSION 
 
RECQL1 is a key member of the RecQ family of DNA helicases. RECQL1 has important 
roles in the maintenance of replication fork progression, DNA repair and gene expression 
mechanisms (3-6). Recently, RECQL1 germ-line mutations were discovered in non-BRCA 
hereditary breast cancer patients (12, 13) implying a critical tumour suppressor function for 
RECQL1. However, the role of RECQL1 in cancer pathogenesis appears to be complex. In 
normal cells, RECQL1 may function as a ‘caretaker of the genome’ (3-6). On the other hand, 
established tumours may be dependent on RECQL1 to tolerate replication induced DNA 
damage, a feature seen in proliferating cancer cells. In fact RECQL1 has been shown to be 
overexpressed in glioblastoma (31), hepatocellular carcinoma (32), ovarian cancers (33), 
melanoma (34)  and head & neck cancer models (35). Whether RECQL1 also impacts 
sporadic breast cancer pathogenesis is currently unknown. We have conducted 
comprehensive analysis and demonstrated prognostic and predictive significance of RECQL1 
in sporadic breast cancers. 
Genomic analyses have revealed that breast cancer represents a heterogeneous group of 
diseases with distinct prognostic outcomes (15). In addition to ER, PR and HER-2 expression 
status, markers of proliferation and genomic stability appear to influence biological and 
clinical behaviour of breast cancers (15, 36, 37). Given the role of RECQL1 in DNA 
replication and repair, we anticipated differential roles of RECQL1 in various molecular sub-
types of breast cancers. As expected, high RECQL1 mRNA was associated with intClust.3 
which is characterised by low genomic instability (15). On the other hand, low RECQL1 
mRNA was linked to intClust.8 luminal A ER+ sub-group (low proliferating) phenotype (15). 
Interestingly, low RECQL1 mRNA was also observed in intClust.9 phenotype which belongs 
to luminal B sub-group implying a more complex role for RECQL1 in this sub-group. In the 
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METABRIC cohort, low RECQL1 mRNA was associated with poor survival. At the protein 
level, similarly, low RECQL1 was associated with aggressive phenotypes and poor survival 
including in ER+ tumours. However, a limitation to the current study is that mRNA 
expression and protein expression studies were conducted in two independent cohort.    
Although, low levels of RECQL1 appear to be prevalent in the breast cancers, the mechanism 
for such down-regulation is currently unknown. As epigenetic silencing of the BRCA1 
promoter has been reported in up to 11%-14% of breast tumours (37), it is likely that similar 
mechanisms may be operating for RECQL1 in sporadic breast cancers. An interesting 
observation was that we did not observe any cytoplasmic staining for RECQL1. This is in 
contrast to the cytoplasmic staining observed for BLM, RECQL4 and WRN in breast cancers 
(16, 38, 39). The data suggests differential regulation of localisation for different RecQ 
helicases.  In pre-clinical studies, RECQL1 deficiency has been shown to promote genomic 
instability resulting in increased frequency of spontaneous sister chromatid exchanges, 
chromosomal instability, DNA damage accumulation and mutagenesis (3-6). A ‘mutator 
phenotype’ (38) due to RECQL1 deficiency may therefore promote an aggressive phenotypes 
in ER+ breast cancers.   In the current study we observed that low PARP1, BRCA1 negative, 
low RAD51, low ATM, low nuclear pChk1, low nuclear Chk2, low XRCC1, low FEN1, low 
SMUG1 and low DNA-PKcs were significantly more likely in tumours with low nuclear 
RECQL1 protein level. The data suggests that RECQL1 loss may increase genomic 
instability which may in turn lead to dysregulation of other DNA repair factors thereby 
promoting a ‘mutator phenotype’. A novel observation in the current study is that low 
RECQL1 also influenced survival in ER+ cohorts that received endocrine therapy implying 
that RECQL1 could also have predictive significance. Given the recent evidence that 
RECQL1 may modulate gene expression (26, 28), we speculate that ER and/or ER mediated 
gene expression could be influenced by low RECQL1 in tumours. To explore this hypothesis 
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we investigated ERα protein levels in control and RECQL1-depleted breast cancer cells. We 
observed significant depletion of ERα levels in RECQL1-depleted MCF-7 and MDA-MB-
231 cells.  The preliminary data would suggest that either RECQL1 depletion impairs ERα 
expression or promotes ERα degradation. Therefore, detailed mechanistic studies are required 
to explore these possibilities in detail. 
In ER- sub-group, RECQL1 did not appear to influence survival either in patient who 
received no chemotherapy or who received historical CMF chemotherapy. Interestingly, in 
ER- negative tumours that received the more modern anthracycline chemotherapy, we 
observed that overexpression of RECQL1 was associated with poor disease free survival. The 
data suggest that ER- tumours may be dependent on RECQL1 to tolerate replication induced 
DNA damage, such as those induced by doxorubicin chemotherapy. To support this 
hypothesis we depleted RECQL1 in breast cancer cells. We  not only demonstrated 
doxorubicin sensitivity in RECQL1-depleted cells but also showed that the observed 
sensitivity was associated with DNA double strand breaks accumulation, S-phase cell cycle 
arrest and apoptosis.    
RecQ family of DNA helicases include RECQL1, RECQL4, RECQL5, BLM and WRN (1, 
2). We have recently investigated the expression of RECQL4, RECQL5, BLM and WRN in 
breast cancers (17, 39-41). Whereas high RECQL4, high RECQL5 and high BLM expression 
were associated with aggressive breast cancers (17, 39, 40), low WRN expression was linked 
to poor outcomes (41). Interestingly, RecQ helicase mRNA levels are linked to biologically 
distinct integrative clusters reported in the METABRIC study (15). For example, intClust 3 
subgroup that is characterised by low genomic instability was consistent seen with tumours 
with low BLM, low RECQL4 and low RECQL5 mRNA levels. On the other hand, high 
RECQL1 or high WRN mRNA levels correlated to intClust 3 sub-group. Similarly, intClust 9 
(8q cis-acting/20qamplified mixed subgroup with aggressive phenotype) was more common 
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in tumours with high BLM, high RECQL4, high RECQL5, low RECQL1 or low WRN mRNA 
levels. Taken together, the mRNA and protein expression data would suggest that differential 
helicase expressions lead to distinct molecular phenotypes. We speculate that proliferative 
functions (of BLM, RECQL4 and RECQL5 helicases) and genomic stability functions (of 
RECQL1 and WRN) may influence breast cancer pathogenesis. Moreover, the data presented 
here would also suggest that RecQ helicase deficient sporadic tumours may be suitable for a 
synthetic lethality approach, an exciting new personalised treatment strategy recently 
demonstrated for PARP inhibitors in BRCA deficient cancers (42).  Moreover, given the 
recent development of helicase inhibitors (1) such as those targeting BLM (43, 44), our data 
would indicate potential application for these new helicase inhibitors for personalization of 
breast cancer therapy.       
In conclusion we have shown that RECQL1 has prognostic and predictive significance in 
breast cancer.    
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Table 1. RECQL1 protein levels and breast cancer.  
   
 
                    VARIABLE 
 
RECQL1 protein level      
 
            P values 
 
     
Low 
N (%) 
High 
N (%) 
Unadjusted   adjusted 
A) Pathological   Parameters  
Tumour Size  
 <1cm 
 >1-2cm 
 >2-5cm 
>5cm 
 
 53 (7.8) 
338 (49.9) 
268 (39.6) 
18 (2.7) 
 
31 (14.1) 
108 (49.1) 
78 (35.5) 
3 (1.4) 
 
0.031 
 
0.0472 
Lymph Node Status                   
Negative 
Positive (1-3) 
Positive (>3) 
 
351 (58.5) 
199 (33.2) 
50 (8.3) 
 
143 (68.8) 
54 (26.0) 
11 (5.3) 
 
0.029 
 
0.0483 
Tumour Stage                                
1 
2 
3 
 
410 (60.5) 
210 (29.6) 
67(9.9) 
 
157 (70.7) 
52 (23.4) 
13 (5.9) 
 
0.017 
 
0.0313 
Tumour Grade                              
 G1 
 G2 
 G3 
 
88 (13.0) 
230 (33.9) 
360 (53.1) 
 
46 (20.9) 
89 (40.5) 
85 (38.6) 
 
0.0001 
 
0.0018 
Mitotic Index  
M1 (low; mitoses < 10) 
M2 (medium; mitoses 10-18) 
M3 (high; mitosis >18) 
 
212 (32.2) 
131 (19.9) 
315 (47.9) 
  
105 (48.2) 
34 (15.6) 
79 (36.2) 
 
0.0001 
 
0.0012 
Tubule Formation                         
1 (>75% of definite tubule) 
2 (10%-75% definite tubule) 
3 (<10% definite tubule) 
 
25 (3.8) 
213 (32.4) 
420 (63.8) 
 
19 (8.7) 
78 (35.8) 
121 (55.5) 
 
0.006 
 
0.0162 
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Pleomorphism                               
1 (small-regular uniform) 
2 (Moderate variation) 
3 (Marked variation) 
 
13 (2.0) 
218 (33.2) 
425 (64.8) 
 
7 (3.2) 
101 (46.5) 
109 (50.2) 
 
0.001 
 
0.0044 
Tumour Type                
IDC-NST 
Tubular Carcinoma 
Medullary Carcinoma 
ILC 
Others 
Mixed NST/lobular/Special Type 
 
421 (63.3) 
122 (18.3) 
17 (2.6) 
63 (9.5) 
8 (1.2) 
34 (5.1) 
 
107 (49.5) 
59 (27.3) 
6 (2.8) 
27 (12.5) 
4 (1.9) 
13 (6.0) 
 
0.017 
 
0.0298 
ER               
Negative 
Positive 
187 (28.1)
478 (71.9)
42 (19.7)
171 (80.3)
 
0.015 0.0309 
PgR                                   
Negative 
Positive 
 
310 (48.0) 
336 (52.0) 
 
67 (31.5) 
146 (68.5) 
 
0.0001 
 
0.0007 
Her2 overexpression                     
No 
Yes 
 
559 (84.1) 
106 (15.9) 
 
197 (90.0) 
22 (10.0) 
 
0.032 
 
0.0431 
Triple Negative Phenotype           
No 
Yes 
 
570 (83.8) 
110 (16.2) 
 
183 (81.7) 
41 (18.3) 
 
0.459 
 
0.4725 
NPI          
≤ 3.4 
>3.4 
 
117 (27.7) 
462 (72.3) 
 
88 (41.5) 
124 (58.5) 
 
0.0001 
 
0.0006 
B) DNA Repair  
XRCC1 (Nuclear)               
Low 
High 
 
98 (18.6) 
430 (81.4) 
 
9 (5.6) 
151 (94.4) 
 
0.0001 
 
0.0005 
BRCA1 (Nuclear)               
Low 
High 
 
104 (18.9) 
447 (81.1) 
 
18 (10.7) 
150 (89.3) 
 
0.014 
 
0.0306 
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SMUG1 (Nuclear)               
Low 
High 
 
288 (58.2) 
207 (41.8) 
 
64 (45.1) 
78 (54.9) 
 
0.002 
 
0.007 
FEN1 (Nuclear)               
Low 
High 
 
389 (75.4) 
127 (24.6) 
 
103 (65.2) 
55 (34.8) 
 
0.012 
 
0.0280 
FEN1 (Cytoplasmic)               
Low 
High 
 
285 (55.2) 
231 (44.8) 
 
70 (44.3) 
88 (55.7) 
 
0.016 
 
0.0311 
PARP1 
Low 
High 
 
270 (49.0) 
281 (51.0) 
 
67 (39.6) 
102 (60.4) 
 
0.033 
 
0.0481 
TOPO2 
Low 
High 
 
237 (47.0) 
267 (53.0) 
 
64 (38.6) 
102 (61.4) 
 
0.057 
 
 
0.0739 
KU 70/80             
Low 
High 
 
60 (13.0) 
400 (87.0) 
 
22 (17.7) 
102 (82.3) 
 
0.181 
 
0.2112 
DNA-PKcs             
Low 
High 
 
87 (18.0) 
397 (82.0) 
 
7 (5.6) 
117 (94.4) 
 
0.001 
 
0.0044 
ATR  
Low 
High 
 
110 (35.4) 
201 (64.6) 
 
38 (37.6) 
63 (62.4) 
 
0.682 
 
23.87 
Chk1 (Nuclear)  
Low 
High 
 
605 (89.1) 
74 (10.9) 
 
164 (73.2) 
60 (26.8) 
 
0.0001 
 
0.0005 
Chk1 (Cytoplasmic)  
Low 
High 
 
211 (31.1) 
468 (68.9) 
 
75 (33.5) 
149 (66.5) 
 
0.451 
 
0.478 
ATM  
Low 
High 
 
238 (56.9) 
180 (43.1) 
 
54 (41.5) 
76 (58.5) 
 
0.002 
 
0.007 
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CHK2                       
Low 
High 
 
112 (25.2) 
333 (74.8) 
 
19 (15.7) 
102 (84.3) 
 
0.029 
 
0.327 
RAD51 (Nuclear)                           
Low 
High 
 
 
234 (55.1) 
191 (44.9) 
 
43 (39.1) 
67 (60.9) 
 
0.003 
 
0.0095 
C) Other RecQ helicases 
 
 
RECQL5 (Nuclear)             
Low 
High 
 
273 (46.5) 
314 (53.5) 
 
68 (40.0) 
102 (60.0) 
 
0.133 
 
0.1605 
RECQL4 (Nuclear)                       
Low 
High 
 
245 (65.9) 
127 (34.1) 
 
173 (50.6) 
169 (49.4) 
 
0.00004 
 
 
0.0014 
RECQL4 (Cytoplasmic)               
Low 
High 
 
297 (53.6) 
257 (46.4) 
 
73 (46.2) 
85 (53.8) 
 
0.100 
 
 
0.125 
BLM (Nuclear)                          
Low 
High 
 
163 (27.7) 
426 (72.3) 
 
28 (16.9) 
138 (83.1) 
 
0.005 
 
 
0.0146 
BLM (Cytoplasmic)                      
Low 
High 
 
438 (74.5) 
150 (25.5) 
 
114 (70.3) 
48 (29.6) 
 
0.292 
 
 
0.3194 
WRN (Nuclear)                          
Low 
High 
 
197 (48.8) 
207 (51.2) 
 
53 (42.1) 
73 (57.9) 
 
0.188 
 
 
0.214 
WRN (Cytoplasmic)                      
Low 
High 
 
221 (54.7) 
183 (45.3) 
 
52 (41.3) 
74 (58.7) 
 
0.008 
 
 
0.02 
Bold = Statistically significant;HER2: human epidermal growth factor receptor 2; ER: 
oestrogen receptor; PgR: progesterone receptor;Triple negative: ER-/PgR-/HER2- .  
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Figure Legends 
Figure 1. RECQL1 mRNA expression and breast cancer survival.  A.  RECQL1 mRNA 
expression and survival in the whole cohort. B.  RECQL1 mRNA expression and survival in 
ER+ tumours. C. RECQL1 mRNA expression and survival in patients with ER+ tumours who 
received endocrine therapy. D. RECQL1 mRNA expression and survival in ER- tumours. E. 
RECQL1 mRNA expression and survival in patients with ER- tumours who received 
chemotherapy. 
Figure 2. RECQL1 protein level and breast cancer survival. A. Photomicrographs of 
RECQL1 protein expression in breast cancers. B.  RECQL1 protein level and survival in the 
whole cohort. C.  RECQL1 protein level and survival in ER+ tumours. D. RECQL1 protein 
level and survival in patients with ER+ tumours who received endocrine therapy. E. 
RECQL1 protein level and survival in patients with ER- tumours who received anthracycline 
chemotherapy. [BCSS= breast cancer specific survival, DFS = Disease free survival]. 
Figure 3. RECQL1 depletion and doxorubicin sensitivity in breast cancer cell lines. A. 
RECQL1 mRNA expression in MCF-7, MDA-MB-231 and MDA-MB-468 breast cancer cell 
lines. B. RECQL1 protein level in MCF-7, MDA-MB-231 and MDA-MB-468 breast cancer 
cell lines.   C. Transient RECQL1 depletion by siRNA (C1) and doxorubicin sensitivity in 
MDA-MB-468 (C2) [The graph shows the cellular surviving fractions measured at different 
doses of doxorubicin treatment in control and RECQL1-depleted cells.  Surviving fraction 
values are the mean ± SEM from three independent experiments]. D. Transient RECQL1 
depletion by siRNA (D1) and doxorubicin sensitivity in MDA-MB-231 (D2) [The graph 
shows the cellular surviving fractions measured at different doses of doxorubicin treatment in 
control and RECQL1-depleted cells.  Surviving fraction values are the mean ± SEM from 
three independent experiments]. E. Stable RECQL1 depletion by shRNA (E1) and 
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doxorubicin sensitivity in MDA-MB-231 (E2) [The graph shows the cellular surviving 
fractions measured at different doses of doxorubicin treatment in control and RECQL1-
depleted cells.  Surviving fraction values are the mean ± SEM from three independent 
experiments]. F. Representative immunofluorescence staining of γH2AX foci (green) and its 
merge with nuclear DNA stain DAPI (blue) in control and RECQL1-depleted MDA-MB-231 
cells is shown here. G. Analysis of γH2AX foci in MDA-MB-231 cells stably transduced 
with control or RECQL1 shRNA. The percentage of cells exhibiting ≥5 γH2AX foci at 
indicated time points following recovery from doxorubicin treatment (0.1 µM for 4 h) was 
determined by immunofluorescence. Quantitative data shown represent the average from two 
independent experiments with associated SEMs.  
Figure 4. RECQL1 depletion and cell cycle progression. A. Cell cycle distributions of 
MDA-MB-231 cells stably transduced with either control or RECQL1 shRNA at the 
indicated times following recovery from doxorubicin treatment (0.1 µM for 4 h). B.  Data 
shown represent the average from two independent experiments with associated SEMs. 
Individual p values are summarized as a table here. C. Sub-G1 population in control and 
RECQL1-depleted MDA-MB-231 cells after doxorubicin treatment (0.1 µM) for indicated 
time. D.  Data shown represent the average from two independent experiments with 
associated SEMs. Individual p values are summarized as a table here.   
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Supplementary Table S1:  Clinicopathological characteristics in the METABRIC cohort  
Variables N (%) 
Age at diagnosis [Median (range)] 61.8 (21.93-96.29) 
Tumour size [Median (range)] 23 (1, 182) 
NPI [Median (95% CI)] 4.46 (4.41-4.51) 
Survival [Median (Months, 95% Cl)] 149 (141-159) 
Lymph nodes status 
 
0 
1 
2 
3 
>3 
 
 
 
1035 
337 
171 
114 
314 
ER status 
 
Positive 
Negative 
Null 
 
 
1497 
438 
42 
PAM50 subtype 
 
Basal  
HER2  
Luminal A  
Luminal B  
Normal  
Not classified 
 
 
 
330 
238 
715 
489 
199 
6 
Adjuvant systemic therapy (AT)  
No AT  305 
Hormone therapy (HT) 1216 
Chemotherapy 416 
Hormone + chemotherapy 192 
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Supplementary Table S2:  Clinicopathological characteristics of Nottingham Tenovus series 
 
Variable n* Cases          (%) 
Menopausal status 1650  
Pre-menopausal  612          (37.0) 
postmenopausal  1038        (63.0) 
Tumour Grade (NGS) 1650  
G1   306          (18.5) 
G2  531          (32.2) 
G3   813          (49.3) 
Lymph node stage 1650  
Negative   1056         (64.0) 
Positive (1-3 nodes)  486          (29.5) 
Positive (>3 nodes)  108           (6.5) 
Tumour size (cm) 1650  
T1 a + b (≤1.0)  187         (11.0) 
T1 c (>1.0 -2.0)  868         (53.0) 
T2 (>2.0-5)  579      (35.0) 
T3 (>5)  16         (1.0) 
Tumour type 1650  
IDC-NST  941         (57) 
Tubular   349         (21) 
ILC  160        (10) 
Medullary (typical/atypical)  41          (2.5) 
Others  159        (9.5) 
NPI subgroups 1650  
Excellent PG(2.08-2.40) Low risk 207         (12.5) 
Good PG(2.42-3.40) 331          (20.1) 
Moderate I PG(3.42 to 4.4) High risk 488         (29.6) 
Moderate II PG(4.42 to 5.4) 395         (23.9) 
Poor PG(5.42 to 6.4) 170         (10.3) 
Very poor PG(6.5–6.8) 59         (3.6) 
3 
 
Survival at 20 years 1650  
Alive and well  1055         (64.0) 
Dead from disease  468          (28.4) 
Dead from other causes  127         (7.6) 
Adjuvant systemic therapy (AT)   
No AT   665         (42.0) 
Hormone therapy (HT)  642         (41.0) 
Chemotherapy  307         (20.0) 
Hormone + chemotherapy  46         (3.0) 
* Number of cases for which data were available. 
NPI; Nottingham prognostic index, PG; prognostic group 
 
 
  
4 
 
Supplemental Table S3: Clinicopathological characteristics of ER- cohort 
Variable  Cases          (%) 
Menopausal status 252  
Pre-menopausal  122      (48.5) 
postmenopausal  130      (51.5) 
Tumour Grade (NGS) 252  
G1     1         (0.3) 
G2    27        (10.6) 
G3  224        (89.1) 
Lymph node stage 252  
Negative    121       (48) 
Positive (1-3 nodes)     86       (34) 
Positive (>3 nodes)      45      (18) 
Tumour size (cm) 252  
T1 a + b (≤1.0)   28        (11) 
T1 c (>1.0 -2.0)  106       (42) 
T2 (>2.0-5)  103       (41) 
T3 (>5)   15       (6) 
Tumour type 252  
IDC-NST  224        (89.0) 
Tubular   5            (2.0) 
ILC  8            (3.0) 
Medullary (typical/atypical)  5            (2.0) 
Others  0            (4.0) 
NPI subgroups 252  
Excellent PG(2.08-2.40) Low risk 0           (0.0) 
Good PG(2.42-3.40) 0           (0.0) 
Moderate I PG(3.42 to 4.4) High risk 111       (44.0) 
Moderate II PG(4.42 to 5.4) 81         (32.0) 
Poor PG(5.42 to 6.4) 38         (15.0) 
Very poor PG(6.5–6.8) 22         (9.0) 
5 
 
Survival at 5 years 252  
Alive and well  176      (70.0) 
Dead from disease    73      (29.0) 
Dead from other causes     3       (1.0) 
NPI; Nottingham prognostic index, PG; prognostic group 
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Supplemental Table S4: Clinicopathological characteristics of BRCA germ-line deficient cohort 
 
Variables BRCA1 (n=50) BRCA2 (n=25) 
Age (years) at diagnosis [Median (range)] 38.5(26-64) 45 (28-71) 
Tumour Size (cm)  
T1 a + b (≤1.0) 
T1 c (>1.0 -2.0) 
T2 (>2.0-5) 
T3 (>5) 
 
7   (22) 
22 (44) 
20 (40) 
1   (2) 
 
2(8) 
8(32) 
13(52) 
2(8) 
Pathological Type 
Ductal/NST 
Lobular/Mixed 
Medullary (Typical/Atypical) 
Basal 
Spindle 
Tubular/Mixed 
 
40 (80) 
1   (2) 
6   (12) 
1   (2) 
1   (2) 
1   (2) 
 
16 (64) 
7(28) 
2(8) 
- 
- 
- 
Grade 
1 
2 
3 
 
1  (2) 
5  (10) 
44 (88) 
 
0(0) 
6(24) 
19(76) 
Stage 
1 
2 
3 
Unknown 
 
32 (64) 
15 (30) 
1  (20) 
2  (4) 
 
16(64) 
7(28) 
2(8) 
0(0) 
Vascular Invasion 
No 
Yes 
Unknown 
 
29 (58) 
17 (34) 
4 (8) 
 
16(64) 
7(28) 
2(8) 
NPI 
NPI <3.4 
NPI ≥3.4 
 
 
3 (6) 
47 (94) 
 
 
2(10) 
18(90) 
Oestrogen receptor (ER)  
Negative  
Positive 
Unknown 
 
40 (80) 
9  (18) 
1 (2) 
 
4(16) 
21(84) 
0(0) 
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Her2 
Negative  
Positive 
Unknown 
 
47 (94) 
2 (4) 
1 (2) 
 
24(96) 
1(4) 
0(0) 
Triple Negativity 
Non TN 
TN 
Unknown 
 
18 (36) 
31 (62) 
1 (2) 
 
23(92) 
2(8) 
Recurrence 
No 
Yes 
 
40 (80) 
10 (20) 
 
19(76) 
6(24) 
Survival in months [Median (range)] 
Alive 
Dead 
118 (9 - 274) 
36 (72) 
14 (28) 
80(0-206) 
18(72) 
7(28) 
Bilateral Cancer 
No 
Yes 
 
34 (68) 
16 (32) 
 
19(76) 
6(24) 
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Supplementary Table S5: Antigens, primary antibodies, clone, source, optimal dilution and scoring system 
used for each immunohistochemical marker 
Antigen Antibody Clone Source Antigen Retrieval 
Dilution 
/  
Incubati
on Time 
Distributio
n 
Scoring 
system Cut-offs 
BRCA1 BRCA1 MS110 Calbiochem Citrate pH6 
1:100 
60 min Nuclear 
% of positive 
cells 
<25% 
(negative) 
 
ATM 
Rabbit 
MAb anti-
ATM 
Y170 Abcam Citrate pH6 1:100 18 hours Nuclear 
% of positive 
cells 
<25% 
(negative) 
 
 
XRCC1 
 
Mouse 
MAb 
Anti-
XRCC1 
 
33-2-5 
 
Thermo-
scientific 
 
Citrate pH6 
 
1:200 
20 min 
 
Nuclear 
 
% of positive 
cells 
 
≥10% (positive) 
APE1 
Rabbit 
anti-APE-
1 
polyclonal 
Novus 
Biological
s 
Citrate pH6 1:500 60 min Nuclear H-score >100 (positive) 
SMUG1 Goat anti-SMUG1 polyclonal 
Acris 
Antibodie
s 
Citrate pH6 1:200 15 min Nuclear H-score ≤35 (negative) 
FEN1 
Rabbit 
anti-
FEN1 
polyclonal 
Novus 
Biological
s 
Citrate pH6 1:200 60 min 
Nuclear  and 
Cytoplasm H-score ≤100 (negative) 
ER 
Mouse 
MAb anti-
ER-α 
SP1 
Dako-
Cytomatio
n 
Citrate pH6 1:150 30 min Nuclear Allred score ≥3 (positive) 
ER 
Mouse 
MAb anti-
ER-α 
EP1 
Dako-
Cytomatio
n 
Citrate pH6 1:80 30 min Nuclear 
% positive 
cells ≥1% positive 
PR 
Mouse 
MAb anti-
PR 
PgR636 
Dako-
Cytomatio
n 
Citrate pH6 1:125 30 min Nuclear 
% positive 
cells ≥1% positive 
CK14 
Mouse 
MAb anti-
Ck14 
LL002 Novocastra Citrate pH6 
1:40 
60 min Cytoplasm 
% of positive 
cells ≥10% (positive) 
Ck6 
Mouse 
MAb anti-
Ck5/6 
D5/161B4 
Dako-
Cytomatio
n 
EDTA pH8 1:100 60 min Cytoplasm 
% of positive 
cells ≥10% (positive) 
Ck18 
Mouse 
MAb anti-
Ck18 
DC10 
Dako-
Cytomatio
n 
Citrate pH6 1:100 60 min Cytoplasm 
% of positive 
cells ≥10% (positive) 
HER2 
Rabbit 
antihuma
n c-erbB2 
polyclonal 
Dako-
Cytomatio
n 
None 1:400 60 min Membrane See text See text 
 
TOP2A 
 
Mouse 
MAb 
 
 
KiS1 
 
Dako-
Cytomatio
n 
 
Citrate pH6 
 
 
1:150 
 
Nuclear/ 
cytoplasm 
 
% of positive 
cells 
 
>25% (positive) 
RECQL5 
Rabbit 
anti 
RecqL5 
Polyclonal Sigma- Aldrich 
Citrate pH6 
 
1:100 
60 min Nuclear H - Score 
≥10 
(positive) 
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BLM Rabbit anti BLM Polyclonal 
Novus-
Biological
s 
Citrate pH6 
 
  1:100 
18 Hours  
Nuclear/ 
Cytoplasmic H- Score 
≥50  
(positive) 
pChk1 
Rabbit 
anti-
pChk1 
Ab58567 Abcam Citrate pH6 1:140 60 min Nuclear H-score ≥50 (High) 
ATR 
Mouse 
MAb 
Anti-ATR 
1E9 
Novus 
Biological
s 
Citrate pH6 1:20 18 hours Nuclear H-score ≥60 (High) 
DNA-
PKcs 
Mouse 
MAb 
Anti- 
3H6 Abcam Citrate pH6 1:1000 20 min Nuclear H-score 
>260 (high) 
 
PARP1 
Mouse 
Anti 
PARP1 
Monoclonal 
7D3-6 
BD 
Pharmige
n 
Citrate pH6 1:1000 20 min Nuclear H-score >80 (High) 
RAD51 
Mouse 
Anti-
RAD51 
Polyclonal Abcam  Citrate pH6 
1:70 
20 min 
Nuclear/ 
Cytoplasmic H-score 
Nuclear ≥8 
(High) 
Cytoplasmic 
≥80 (High) 
WRN 
Rabbit 
Anti-
WRN 
Polyclonal 
Novus 
Biological
s 
Citrate pH6 
1:100 
Overnight 
(18h) 
Nuclear/ 
Cytoplasmic H-score 
Nuclear 
≥116(High) 
Cytoplasmic 
≥20 (High) 
RECQL4 
Rabbit 
Anti  
RECQL4 
Polyclonal 
Novus 
Biological
s 
Citrate pH6 1:175 20 min 
Nuclear/ 
Cytoplasmic H-score 
Nuclear ≥30 
(High) 
Cytoplasmic 
≥100 (High) 
 
Chk2 Rabbit Anti Chk2 Polyclonal Abcam Citrate pH6 
1:100 
20 min Nuclear H-Score Nuclear ≥100 
Ku 70/80 
Mouse 
Anti 
Ku70/80 
Monoclonal Abcam Citrate pH6 1:2500 20 min Nuclear H-score >90 (High) 
 
All sections were pre-treated with microwave antigen retrieval using 0.1% citrate buffer (pH 6) except for 
HER2 (no pre-treatment) and EGFR (pre-treated with protease for 10 minutes).   
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Supplementary Table S6. RecQL1 mRNA expression and breast cancer. 
 
 
 
 
VARIABLE 
 
 
RecQL1 mRNA Expression  
 
 
P Values 
Low High 
Unadjusted adjusted 
N(%) N (%) 
A) Pathological    Parameters  
Lymph node stage   
Negative 345(55.1%) 690(51.3%) 0.283 
 
0.3872 
 
 
Positive (1-3) 93(14.9%) 221(16.4%) 
Positive (>3) 188(30.0%) 434(32.3%) 
Grade  
G1 52(8.8%) 117(9.0%) 0.018 0.0668 
 G2 268(45.4%) 502(38.6%) 
G3 270(54.8%) 680(52.3%) 
Tumour Size (cm)  
T 1a+b(1.0) 36(5.8%) 56(4.2%) 0.20 0.325 
 T 1c(>1.0-2.0) 228(36.8%) 538(40.2%) 
T2 (>2.0-5) 328(52.9%) 673(50.3%) 
T3 (>5) 28(4.5%) 70(5.2%) 
NPI  
≤ 3.4 132(22.5%) 259(20.1%) 0.236 0.3609 
 >3.4 454(77.5%) 1028(79.9%) 
  
Her2 overexpression (No)  550(87.9%) 1182(87.5%) 0.817 21.242 
                               (Yes) 76(12.1%) 169(12.5%) 
Triple negative          (No)        549(87.7) 1111(82.2) 0.002 0.052 
                                (Yes)  77(12.3) 240(17.8) 
ER                   (Negative) 128(20.4%) 342(25.3%) 0.018 0.0585 
                        (Positive) 498(79.6%)  1009(74.7%) 
11 
 
PgR                  (Negative) 287(45.8%) 649(48.0%) 0.364 0.4506 
                          (Positive) 339(54.2%) 702(52.0%) 
Genefu subtype  
ER-/Her-2 negative 43(13.9%) 107(15.6%) 0.487 0.575 
 
ER+/Her-2 negative/high 
proliferation 109(35.3%) 257(37.5%) 0.497 
0.561 
 
ER+/Her-2 negative/low 
proliferation 
129(41.7%) 239(34.9%) 0.038 
 
 
0.0898 
 
 
Her-2 positive 
28(9.1%) 82(12.0%) 0.176 
0.3268 
 
 
PAM50 subtype  
PAM50.Her2 87(15.6%) 151(12.4%) 0.067 0.145 
 
PAM50.Basal   86(15.4%) 244(20.1%) 0.020 0.0563 
 
PAM50.LumA 246(44.2%) 469(38.6%) 0.027 0.0702 
 
 
PAM50.LumB 138(24.8%) 351(28.9%) 0.072 0.144 
 
IntClust subgroups  
intClust.1 38(6.1%) 99(7.3%) 0.306 0.3978 
intClust.2 28(4.5%) 44(3.3%) 0.179 0.31 
intClust.3  69(11.0%) 221(16.4%) 0.002 0.026 
intClust.4 100(16.0%) 243(18.0%) 0.272 0.39 
intClust.5 58(9.3%) 131(9.7%) 0.762 0.825 
intClust.6 26(4.2%) 60(4.4%) 0.770 0.8008 
intClust.7 75(12.0%) 114(8.4%) 0.013 0.0563 
intClust.8 115(18.4) 185(13.7%) 0.007 0.0455 
intClust.9 62(9.9%) 84(6.2%)        0.004      0.0346 
intClust.10 55(8.8%) 170(12.6%) 0.013 0.0676 
12 
 
Bold = Statistically significant;HER2: human epidermal growth factor receptor 2; ER: oestrogen 
receptor; PgR: progesterone receptor;Triple negative: ER-/PgR-/HER2- .  
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Supplementary Table S7. RECQL1 protein levels and ER+ breast cancers.  
   
 
                    VARIABLE 
 
RECQL1 protein level 
                   
     
          P- values 
 
Low 
N (%) 
 
High 
N (%) 
unadjusted adjusted 
A) Pathological   Parameters  
Tumour Size  
 <1cm 
 >1-2cm 
 >2-5cm 
>5cm 
 
 44 (9.2) 
247 (51.9) 
175 (36.8) 
10 (2.1) 
 
24 (14.3) 
88 (52.4) 
55 (32.7) 
1 (0.6) 
 
0.157 
 
0.3701 
Tumour Stage                                 
1 
2 
3 
 
 
285 (59.7) 
146 (30.6) 
46 (9.6) 
 
120 (70.6) 
40 (23.5) 
10 (5.9) 
 
0.037 
 
0.184 
Tumour Grade                              
 G1 
 G2 
 G3 
  
 
82 (17.2) 
210 (44.0) 
185 (38.8) 
 
42 (25.0) 
82 (48.8) 
44 (26.2) 
 
0.006 
 
0.066 
Mitotic Index  
M1 (low; mitoses < 10) 
M2 (medium; mitoses 10-18) 
M3 (high; mitosis >18) 
 
198 (42.8) 
110 (23.8) 
155 (33.5) 
  
97 (58.4) 
30 (18.1) 
39 (23.5) 
 
0.002 
 
0.033 
Tubule Formation                          
1 (>75% of definite tubule) 
2 (10%-75% definite tubule) 
3 (<10% definite tubule) 
 
23 (5.0) 
182 (39.3) 
258 (55.7) 
 
16 (9.6) 
69 (41.6) 
81 (48.8) 
 
0.063 
 
0.1848 
 
 
 
Pleomorphism                                
1 (small-regular uniform) 
2 (Moderate variation) 
3 (Marked variation) 
 
12 (2.6) 
206 (44.7) 
243 (52.7) 
 
5 (3.0) 
93 (56.4) 
67 (40.6) 
 
0.028 
 
0.231 
Tumour Type                
IDC-NST 
Tubular Carcinoma 
Medullary Carcinoma 
 
253 (53.8) 
114 (24.3) 
1 (0.2) 
 
69 (41.8) 
54 (32.7) 
0 (0.0) 
 
0.142 
 
0.249 
14 
 
ILC 
Others 
Mixed NST/lobular/Special Type 
63 (13.4) 
7 (1.5) 
32 (6.8) 
26 (15.8) 
4 (2.4) 
12 (7.3) 
Lymph Node Status                   
Negative 
Positive (1-3) 
Positive (>3) 
 
249 (58.6) 
141 (33.2) 
35 (8.2) 
 
110 (68.8) 
42 (26.3) 
8 (5.0) 
 
0.067 
 
0.231 
PgR                                   
Negative 
Positive 
 
128 (28.0) 
329 (72.0) 
 
22 (13.4) 
142 (86.6) 
 
0.0001 
 
0.0033 
Her2 overexpression                     
No 
Yes 
 
419 (89.7) 
48 (10.3) 
 
158 (94.6) 
9 (5.4) 
 
0.058 
 
0.239 
Triple Negative Phenotype               
No 
Yes 
 
401 (83.9) 
77 (16.1) 
 
146 (85.4) 
25 (14.6) 
 
0.646 
 
0.8422 
NPI          
≤ 3.4 
>3.4 
 
165 (36.6) 
286 (63.4) 
 
80 (49.7) 
81 (50.3) 
 
0.002 
 
0.033 
B) DNA Repair 
 
 
 
XRCC1 (Nuclear)               
Low 
High 
 
49 (13.1) 
326 (86.9) 
 
4 (3.1) 
123 (96.9) 
 
0.002 
 
0.0332 
BRCA1 (Nuclear)               
Low 
High 
 
44 (11.2) 
350 (88.8) 
 
12 (8.8) 
124 (91.2) 
 
0.443 
 
0.7056 
SMUG1 (Nuclear)               
Low 
High 
 
170 (50.1) 
169 (49.9) 
 
48 (43.6) 
62 (56.4) 
 
0.235 
 
0.346 
FEN1 (Nuclear)               
Low 
High 
 
268 (73.2) 
98 (26.8) 
 
73 (60.2) 
48 (39.7) 
 
0.007 
 
0.066 
FEN1 (Cytoplasmic)               
Low 
High 
 
203 (55.5) 
163 (44.5) 
 
54 (44.6) 
67 (55.4) 
 
0.038 
 
0.7077 
PARP1 
Low 
High 
 
188 (49.3) 
193 (50.7) 
 
53 (40.5) 
78 (59.5) 
 
0.079 
 
0.936 
15 
 
TOPO2 
Low 
High 
 
171 (49.1) 
177 (50.9) 
 
49 (38.6) 
78 (61.4) 
 
0.041 
 
 
0.0253 
KU 70/80             
Low 
High 
 
32 (10.3) 
280 (89.7) 
 
15 (16.5) 
76 (83.5) 
 
0.103 
 
0.376 
DNA-PKc             
Low 
High 
 
56 (16.7) 
279 (83.3) 
 
6 (6.6) 
85 (93.4) 
 
0.015 
 
0.1848 
ATR  
Low 
High 
 
106 (47.3) 
118 (52.7) 
 
39 (51.3) 
37 (48.7) 
 
0.547 
 
0.834 
pChk1 (Nuclear)  
Low 
High 
 
419 (87.8) 
58 (12.2) 
 
125 (73.1) 
46 (26.9) 
 
0.0001 
 
0.0033 
pChk1 (Cytoplasmic)  
Low 
High 
 
156 (32.7) 
321 (67.3) 
 
62 (36.3) 
109 (63.7) 
 
0.399 
 
0.6534 
ATM  
Low 
High 
 
155 (53.4) 
135 (46.6) 
 
37 (36.6) 
64 (63.4) 
 
0.004 
 
0.0610 
CHK2                       
Low 
High 
 
64 (20.9) 
242 (79.1) 
 
14 (15.4) 
77 (84.6) 
 
0.244 
 
0.245 
RAD51 (Nuclear)                            
Low 
High 
 
 
144 (50.0) 
144 (50.0) 
 
31 (37.3) 
52 (62.7) 
 
0.042 
 
0.705 
C) Other RecQ helicases 
 
 
RECQL5 (Nuclear)             
Low 
High 
 
184 (44.8) 
227 (55.2) 
 
47 (35.9) 
84 (64.1) 
 
0.073 
 
0.0660 
RECQL4 (Nuclear)                          
Low 
High 
 
206 (53.5) 
179 (46.5) 
 
52 (50.8) 
60 (49.2) 
 
0.109 
 
 
0.376 
RECQL4 (Cytoplasmic)                          
Low 
High 
 
223 (60.1) 
148 (39.9) 
 
147 (43.1) 
194 (56.9) 
 
0.604 
 
 
0.8422 
BLM (Nuclear)                          
Low 
High 
 
89 (21.6) 
323 (78.4) 
 
22 (17.1) 
107 (82.9) 
 
0.264 
 
 
0.3716 
16 
 
BLM (Cytoplasmic)                          
Low 
High 
 
298 (72.5) 
113 (27.5) 
 
93 (72.7) 
35 (27.3) 
 
0.973 
 
 
0.968 
WRN (Nuclear)                          
Low 
High 
 
140 (49.8) 
141 (50.2) 
 
40 (40.8) 
58 (59.2) 
 
0.124 
 
 
0.376 
WRN (Cytoplasmic)                          
Low 
High 
 
149 (53.0) 
132 (47.0) 
 
38 (38.8) 
60 (61.2) 
 
0.015 
 
 
0.261 
Bold = Statistically significant;HER2: human epidermal growth factor receptor 2; ER: oestrogen receptor; PgR: 
progesterone receptor;Triple negative: ER-/PgR-/HER2- .  
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Supplementary Table S8. RECQL1 protein levels and ER- breast cancers.  
   
 
                    VARIABLE 
 
RECQL1 protein level 
                   
 
 
   P- values 
Low 
N (%) 
 
High 
N (%) 
A) Pathological   Parameters 
Tumour Size  
 <1cm 
 >1-2cm 
 >2-5cm 
>5cm 
 
 9 (4.8) 
83 (44.6) 
87 (46.8) 
7 (3.8) 
 
5 (11.9) 
15 (35.7) 
20 (47.6) 
2 (4.8) 
 
0.319 
Tumour Stage                                 
1 
2 
3 
 
 
115 (61.8) 
51 (27.4) 
20 (10.8) 
 
29 (69.0) 
10 (23.8) 
3 (7.1) 
 
0.640 
Tumour Grade                              
 G1 
 G2 
 G3 
  
 
4 (2.2) 
14 (7.5) 
168 (90.3) 
 
1 (2.4) 
5 (11.9) 
36 (85.7) 
 
0.645 
Mitotic Index  
M1 (low; mitoses < 10) 
M2 (medium; mitoses 10-18) 
M3 (high; mitosis >18) 
 
11 (6.1) 
16 (8.8) 
154 (85.1) 
  
3 (7.1) 
4 (9.5) 
35 (83.3) 
 
0.955 
Tubule Formation                          
1 (>75% of definite tubule) 
2 (10%-75% definite tubule) 
3 (<10% definite tubule) 
 
2 (1.1) 
26 (14.4) 
153 (84.5) 
 
1 (2.4) 
5 (11.9) 
36 (85.7) 
 
0.753 
Pleomorphism                                
1 (small-regular uniform) 
2 (Moderate variation) 
3 (Marked variation) 
 
1 (0.6) 
7 (3.9) 
173 (95.6) 
 
0 (0.0) 
5 (11.9) 
37 (88.1) 
 
0.104 
Tumour Type                
IDC-NST 
Tubular Carcinoma 
Medullary Carcinoma 
 
158 (87.8) 
5 (2.8) 
15 (8.3) 
 
34 (82.9) 
1 (2.4) 
5 (12.2) 
 
0.701 
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Others 
Mixed NST/lobular/Special Type 
1 (0.6) 
1 (0.6) 
0 (0.0) 
1 (2.4) 
 
Lymph Node Status                   
Negative 
Positive (1-3) 
Positive (>3) 
 
96 (58.2) 
54 (32.7) 
15 (9.1) 
 
27 (67.5) 
10 (25.0) 
3 (7.5) 
 
0.556 
PgR                                   
Negative 
Positive 
 
175 (99.4) 
1 (0.6) 
 
41 (100.0) 
0 (0.0) 
 
0.629 
Her2 overexpression                     
No 
Yes 
 
128 (69.6) 
56 (30.4) 
 
32 (76.2) 
10 (23.8) 
 
0.394 
Triple Negative Phenotype               
No 
Yes 
 
157 (84.0) 
30 (16.0) 
 
30 (71.4) 
12 (28.6) 
 
0.058 
 
NPI          
≤ 3.4 
>3.4 
 
7 (4.0) 
166 (96.0) 
 
4 (9.8) 
37 (90.2) 
 
0.137 
B) DNA Repair 
 
 
XRCC1 (Nuclear)               
Low 
High 
 
45 (31.9) 
96 (68.1) 
 
5 (18.5) 
22 (81.5) 
 
0.163 
BRCA1 (Nuclear)               
Low 
High 
 
55 (37.2) 
93 (62.8) 
 
6 (20.7) 
23 (79.3) 
 
0.088 
SMUG1 (Nuclear)               
Low 
High 
 
113 (77.4) 
33 (22.6) 
 
14 (58.3) 
10 (41.7) 
 
0.046 
FEN1 (Nuclear)               
Low 
High 
 
109 (80.1) 
27 (19.9) 
 
25 (80.6) 
6 (19.4) 
 
0.950 
FEN1 (Cytoplasmic)               
Low 
High 
 
76 (55.9) 
60 (44.1) 
 
15 (48.4) 
16 (51.6) 
 
0.449 
PAPR1 
Low 
High 
 
76 (47.5) 
84 (52.5) 
 
14 (48.3) 
15 (51.7) 
 
0.939 
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TOPO2 
Low 
High 
 
60 (42.0) 
83 (58.0) 
 
13 (40.6) 
19 (59.4) 
 
0.890 
 
KU 70/80             
Low 
High 
 
25 (18.1) 
113 (81.9) 
 
4 (15.4) 
22 (84.6) 
 
0.738 
DNA-PKc             
Low 
High 
 
26 (18.7) 
113 (81.3) 
 
1 (3.7) 
26 (96.3) 
 
0.053 
ATR  
Low 
High 
 
36 (43.9) 
46 (56.1) 
 
9 (50.0) 
9 (50.0) 
 
0.638 
pChk1 (Nuclear)  
Low 
High 
 
174 (93.0) 
13 (7.0) 
 
31 (73.8) 
11 (26.2) 
 
0.0001 
pChk1 (Cytoplasmic)  
Low 
High 
 
47 (25.1) 
140 (74.9) 
 
11 (26.2) 
31 (73.8) 
 
0.887 
ATM  
Low 
High 
 
 78 (64.5) 
43 (35.5) 
 
15 (55.6) 
12 (44.4) 
 
0.386 
CHK2                       
Low 
High 
 
43 (32.8) 
88 (67.2) 
 
4 (18.2) 
18 (81.8) 
 
0.168 
RAD51 (Nuclear)                            
Low 
High 
 
 
83 (65.9) 
43 (34.1) 
 
11 (55.0) 
9  (45.0) 
 
0.346 
C) Other RecQ helicases 
 
RECQL5 (Nuclear)             
Low 
High 
 
83 (50.9) 
80 (49.1) 
 
16 (53.3) 
14 (46.7) 
 
0.808 
RECQL4 (Nuclear)                          
Low 
High 
 
118 (75.2) 
39 (24.8) 
 
16 (59.3) 
11 (40.7) 
 
0.086 
 
RECQL4 (Cytoplasmic)                          
Low 
High 
 
87 (55.4) 
70 (44.6) 
 
8 (29.6) 
19 (70.4) 
 
0.013 
 
BLM (Nuclear)                          
Low 
High 
 
69 (42.1) 
95 (57.9) 
 
5 (16.7) 
25 (83.3) 
 
0.008 
 
20 
 
BLM (Cytoplasmic)                          
Low 
High 
 
129 (78.7) 
35 (21.3) 
 
20 (71.4) 
8 (28.6) 
 
0.396 
 
WRN (Nuclear)                          
Low 
High 
 
51 (45.9) 
60 (54.1) 
 
10 (47.6) 
11 (52.4) 
 
0.888 
 
WRN (Cytoplasmic)                          
Low 
High 
 
65 (58.6) 
46 (41.4) 
 
11 (52.4) 
10 (47.6) 
 
0.599 
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Supplementary Figure Legends 
 
Supplementary Figure S1. RECQL1 and survival in ER+ or ER- breast cancer patients. 
A. RECQL1 protein level and survival in patients with ER+ tumours who received no 
endocrine therapy. B. RECQL1 protein level and survival in ER- tumours. C. RECQL1 
protein level and survival in patients with ER- tumours who received CMF 
(cyclophosphamide, methotrexate, 5-Fluorouracil) chemotherapy. D. RECQL1 protein level 
and survival in patients with ER- tumours who received no chemotherapy [BCSS= breast 
cancer specific survival]. 
Supplementary Figure S2. RECQL1-depleted MCF-7 cells exhibit sensitivity to 
doxorubicin.  A. Transient knockdown of RECQL1 using siRNAs (A1) and doxorubicin 
sensitivity in MCF-7 cells (A2) is shown here.  Depletion of RECQL1 was assessed by 
Western blot.  The graphs show the cellular surviving fractions measured at different doses of 
doxorubicin treatment in control and RECQ1-depleted cells.  Surviving fraction values are 
the mean ± SEM from three independent experiments. B. Analysis of γH2AX foci in control 
and RECQL1 knockdown MCF-7 cells.  Cells were exposed to 0.1 µM doxorubicin for 4h 
and recovered in drug-free medium.  The percentage of cells exhibiting >5 γH2AX foci at 
indicated time points following recovery from doxorubicin treatment was determined by 
immunofluorescence.  Quantitative data shown represent the average from two independent 
experiments with associated SEMs.  The statistical significance of the difference between the 
percentage of γH2AX positive control and RECQL1 knockdown cells is indicated (p≤ 0.05 
indicated by *; p≤ 0.005 indicated by **). C. Cell cycle distributions of control and RECQL1 
knockdown MCF-7 cells at the indicated times following recovery from doxorubicin 
treatment (0.1 µM for 4 h).  Data shown represent the average from two independent 
experiments with associated SEMs.  D. Sub-G1 population in control and RECQL1 depleted 
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MCF-7 cells after doxorubicin treatment (0.1 µM) for indicated time.  Data shown represent 
the average from two independent experiments with associated SEMs.  The statistical 
significance is indicated (p≤ 0.05 indicated by *; p≤ 0.005 indicated by **, compared to 
control siRNA). 
 
Supplementary Figure S3. RECQL1 depletion and ERα protein levels. Western blot 
detection of ERα in extracts derived from MDA-MB-468, MDA_MB-231, and MCF-7 cells 
at 48 h following transfection with control or RECQL1 siRNA.  Fifty µg total protein was 
loaded in each lane and ERα Ab (EP1 clone) was used at 1:100 dilution.  Bottom panel shows 
longer exposure of the same blot including molecular weight marker.  Knockdown of 
RECQL1 was confirmed and GAPDH was used as a loading control.   
 


